- On 6 August 2026, CellCarta Inc. said it would add Tempus AI to its CDx Commercialization Lab Network, with Tempus using its Tempus Hub to manage provider test ordering, sample routing to CellCarta, and result delivery for oncology-focused companion diagnostics in the U.S.
- This collaboration links Tempus AI’s ordering and data platform with CellCarta’s development and regulatory capabilities, aiming to close the gap between CDx approval and real-world clinical access for cancer patients.
- We’ll now examine how Tempus AI’s new role in CellCarta’s CDx network could reshape the company’s investment narrative and growth drivers.
AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Tempus AI Investment Narrative Recap
To own Tempus AI, you need to believe that its AI data and diagnostics platforms can translate deep clinical integration into durable, profitable demand from oncologists and biopharma partners. The CellCarta collaboration could support that thesis by embedding Tempus Hub more tightly into oncology workflows, potentially reinforcing the near term catalyst around execution on raised 2026 revenue guidance and platform adoption, while leaving the core risks of competition, reimbursement timing, and heavy AI investment firmly in view.
Among recent announcements, the PRISM2 pathology foundation model matters most in this context, because it highlights how Tempus is trying to turn its scale in multimodal data into differentiated AI diagnostics. When combined with Tempus Hub’s ordering and reporting role in CellCarta’s CDx network, PRISM2 points to a tighter link between Tempus’s AI models, real world testing volumes, and the company’s ability to justify ongoing R&D and compute spending to investors.
Yet beneath the promise of deeper oncology integration, investors should also understand how reimbursement delays and mounting AI infrastructure costs could...
Read the full narrative on Tempus AI (it's free!)
Tempus AI's narrative projects $2.4 billion revenue and $374.7 million earnings by 2029. This requires 20.8% yearly revenue growth and an earnings increase of about $677.6 million from -$302.9 million today.
Uncover how Tempus AI's forecasts yield a $66.53 fair value, a 28% upside to its current price.
Exploring Other Perspectives
Some of the lowest estimate analysts were assuming roughly US$2.4 billion of revenue and no profitability by 2029, so compared with the current CDx momentum and AI build out they are effectively saying, “even if these tools work, commercialization and margins could lag much longer than the consensus expects,” which is a reminder that your own view on Tempus AI should weigh both this caution and the upside that partnerships like CellCarta might unlock.
Explore 8 other fair value estimates on Tempus AI - why the stock might be worth over 2x more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Tempus AI research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.
Curious About Other Options?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Find 51 companies with promising cash flow potential yet trading below their fair value.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com